Category Archives: Stem Cell Research

Acred Cells?: Why Christians Should Support Stem Cell
ll4.me Acred Cells?: Why Christians Should Support Stem Cell Unknown to most outside observers, from the earliest days of embryonic stem cell research through today #39;s latest developments, Christian theologians have been actively involved with leading laboratory research scientists to determine the ethical implications of stem cell research. And contrary to popular expectation, these Christians have been courageously advocating in favor of research. Three of these dynamic theologians tell their story in Sacred Cells? Why Christians Should Support Stem Cell Research. Sacred Cells? takes readers through the twists and turns of stem cell development, providing a brief history of the science and an overview of the competing ethical frameworks people use in approaching the heated debate. Each new scientific advance, from the cloning of Dolly the sheep to the use of engineered cells in humans, had to be carefully considered before proceeding. Rejecting the widely held belief that the ethics of stem cell research turn on the moral status of the embryo, the authors carefully weigh a diversity of ethical problems. Ultimately, they embrace stem cell research and the prospect of increased health and well being it offers. Author: Peters, Ted Publisher: Rowman Littlefield Publishers, Inc. Illustration: N Language: ENG Title: Sacred Cells? Pages: 00272 Unknown to most outside observers, from the earliest days of embryonic stem cell research through today #39;s latest developments ...From:kennethbishop615Views:0 0ratingsTime:00:13More inPeople Blogs

Read more:
Acred Cells?: Why Christians Should Support Stem Cell - Video

Govt. Appoints Task Force To Explore Stem Cell Research
Minister of Health Hon. Dr. Perry Gomez announced that the government has appointed a 10 member task force, charged with making recommendations to the government to explore stem cell therapy in The Bahamas.From:ZNSNetworkViews:5 0ratingsTime:03:27More inNews Politics

Continue reading here:
Govt. Appoints Task Force To Explore Stem Cell Research - Video

The Biotech Age: The Business Of Biotech And How To Profit From It - Richard Oliver
ll4.me The Biotech Age: The Business Of Biotech And How To Profit From It - Richard Oliver A look at the forefront of an industry revolution ""I #39;ve been deep inside the biotech industry since its infancy. This book provides fresh insights about how it started, what drives it, and most importantly, where it #39;s going.""--Scott W. Morrison, partner, Ernst Young LL Richard W. Oliver predicted the onset of a new era with The Coming Biotech Age. Now that age is here--and companies are reaping the benefits of this incredible new revolution. As biotech companies become the new economic engines of growth and innovation, businesses must have access to the latest developments of this area of research. In a special revised edition, now titled The Biotech Age, Oliver has created the first practical guide to this fascinating realm of scientific development. With updated information on the latest research, examples of biotech breakthroughs, and a close examination of current biotech issues such as cloning and stem cell research, The Biotech Age presents an accessible overview of the business of biotechnology and its vast implications and opportunities for all types of industries. This is a topic no one can afford to miss--especially future-minded executives and investors in cutting-edge technologies.Words: and opportunities, companies it, how deep is, inside from, it must have, must have it, young ernstAuthor: Oliver, Richard Publisher: McGraw-Hill Illustration: N Language: ENG Title ...From:jonisims9854Views:0 0ratingsTime:00:10More inPeople Blogs

The rest is here:
The Biotech Age: The Business Of Biotech And How To Profit From It - Richard Oliver - Video

Integrating History And Philosophy Of Science
ll4.me Integrating History And Philosophy Of Science From the contents: Introduction by Seymour Mauskopf and Tad Schmaltz Part I: General Reflections Thomas Kuhn and Interdisciplinary Conversation: Why Historians and Philosophers of Science Stopped Talking to One Another , Jan Golinski The History and Philosophy of Science History, David M. Miller What in Truth Divides Historians and Philosophers of Science?, Kenneth Caneva History and Philosophy of Science: Recollections and Reflections, Ronald Giere Philosophy of Science and Its Historical Reconstructions , Peter Dear The Underdetermination Debate: How Lack of History Leads to Bad Philosophy, Wolfgang Pietsch Part II: Case Studies Beyond Case Studies: History as Philosophy, Hasok Chang Hidden Entities and Experimental Practice: Renewing the Dialogue between History and Philosophy of Science, Theodore Arabatzis Studying Methodological Thought: S. Weir Mitchell s Research on the Venom of Poisonous Snake, Jutta Schickore Quantum Gravity: History, Historiography and Philosophy, Dean Rickles Social Epistemology of Stem Cell Research: History, Philosophy and Experiment, Melinda Fagan History and Philosophy of Science at Work: Making Regenerative Medicine Better EAN/ISBN : 9789400717459 Publisher(s): Springer, Berlin, Springer Netherlands Discussed keywords: Geschichtsschreibung, Interdisziplinaritt, Wissenschaftsphilosophie Format: ePub/PDF Author(s): Mauskopf, Seymour - Schmaltz, Tad From the contents: Introduction by ...From:susanbranch9865Views:0 0ratingsTime:00:16More inPeople Blogs

Continue reading here:
Integrating History And Philosophy Of Science - Video

90 DAYS, 90 REASONS #79 Because President Obama Supports Stem Cell Research
Romney, meanwhile, has managed to stake out equivocating, obfuscating, and disingenuous stances on the issue. The anti-choice right wing, which defines stem cell research as an equivalent to abortion, believes that Romney shares their extremist position. Romney himself claims to support the "scientific alternative," known as iPS, without acknowledging mdash;or could he somehow not know? mdash;that iPS requires stem cell research to progress; the two presently go hand in hand, or not at all.From:vidhead85Views:0 0ratingsTime:02:44More inNews Politics

Read the original:
90 DAYS, 90 REASONS #79 Because President Obama Supports Stem Cell Research - Video

stem cell banking | Knowing More About Cord Blood Banking
http://www.cordbloodrecommendation.com The umbilical cord blood is rich in stem cells as the baby #39;s organs, tissues and body is developed by it. Diseases that are genetically based would most likely be an allogenic transplant. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. There is also another option given by non-profit cord blood banks, of free programs through which one can store umbilical cord blood stem cell samples. A man can change his god-gifted features wishfully with the help of science. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. One study in particular by Wagner, et al. ""The theory exists that any reduction in the volume of umbilical cord blood units in albumin or dextran prior to transfusing into patients leads to better cell viability. The mother will be informed about the status of the blood unit and the test results so that she is aware of any infection or disease that might affect her baby. Many parents see placental and cord blood banking as valuable tools to help them secure potentially ...From:fivespanishViews:0 0ratingsTime:01:18More inScience Technology

Go here to see the original:
stem cell banking | Knowing More About Cord Blood Banking - Video

California's historic Proposition 71 provided big money for stem-cell research after voters approved it eight years ago. The measure helped fund major advances, but some charge that the success has been hampered by cronyism and conflict of interest.

Roman Reed has been a paraplegic for more than eighteen years. Ever since a college football injury injured his spine. Reed says he's confident he will walk again.

"Stem cells are going to get me out of this chair. I will walk again one day because of stem cell research," said Reed.

He campaigned hard for Prop 71 eight years ago. Voters believed stem cells might help find cures for paralysis, heart disease, diabetes and more.

The proposition won and the California Institute for Regenerative Medicine or CIRM received $3 billion from taxpayers. The bond money was intended to find stem cell cures.

Some are starting to question whether they have found any.

"We do not have any cures, nor did we expect to have any cures within the time frame that we've funded so far," said CIRM's Chairman Jonathon Thomas.

They have spent $1.7 billion dollars to date. The money has been used to build a dozen new laboratories. It has also funded 1200 papers on 38 incurable diseases and lured 150 top scientists to California.

CIRM is backing seven clinical trials, but the FDA has not approved even one stem-cell therapy procedure. Six months ago, U.S. doctors got the green light to use a Canadian treatment for dying children.

Director of Stem Cell Program at UC Davis Institute for Regenerative Cures Jan Nolta believes it is a great advancement in medicine.

Originally posted here:
Some critics impatient over slow stem-cell research payoff

cryocell | Why Store Your Cord Blood In a Bank?
http://www.cordbloodrecommendation.com A large number of people die waiting for a transplant due to this reason. Before any blood donations are made it is important for a pregnant mother interested to make the donation to contact the bank before the thirty fourth week of her pregnancy. However, private banking is generally not recommended unless there is a family history of specific genetic diseases. It contains stem cells that have been found to be excellent for research and treatment of many diseases. A man can change his god-gifted features wishfully with the help of science. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. One study in particular by Wagner, et al. ""Settling on a name for your newborn is definitely something all parents spend time doing, but one decision that is rarely thought of or overlooked is saving your newborn #39;s cord blood. The mother will be informed about the status of the blood unit and the test results so that she is aware of any infection or disease that might affect her baby. Many parents see placental and cord blood banking as valuable tools to help them secure potentially lifesaving treatment options their families may some day ...From:loshoteles enmedellinViews:0 0ratingsTime:01:18More inScience Technology

See original here:
cryocell | Why Store Your Cord Blood In a Bank? - Video

TORONTO, ONTARIO--(Marketwire - Nov. 7, 2012) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network ("UHN"), through its commercialization agent MaRS Innovation ("MI"), both of Toronto. The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program.

Based on Dr. Aaron Schimmer's award-winning research, the technology has provided compelling evidence that tigecycline, an FDA-approved antibiotic, is able to selectively target leukemia cells and leukemic stem cells by shutting down their energy supply through the inhibition of mitochondrial protein synthesis.

Dr. Schimmer, Associate Professor in the University of Toronto's Department of Medical Biophysics and a clinician-scientist in the Princess Margaret Cancer Centre/Ontario Cancer Institute at University Health Network, published his findings in 2011 in the journal Cancer Cell. Based on this discovery, Dr. Schimmer received the 2012 Till & McCulloch Award presented each year by the Stem Cell Network to recognize the year's most influential peer-reviewed article by a researcher in Canada.

"In recent years Dr. Schimmer has had a widely-recognized rise to become one of Canada's premier clinician-scientists," commented David Allan, Executive Chairman of SCT. "He is following in the steps and traditions of other world-renowned Canadian stem cell researchers such as Drs. Ernest McCulloch, James Till and John Dick. We are fortunate to be the commercial partner on what we believe will be an exciting journey to new cancer stem cell-specific products. Repositioning a safe and well-tolerated antibiotic as a cancer therapeutic is an attractive business proposition for SCT, particularly when it is backed by strong science, sufficient differentiation from the original product, and strong intellectual property protecting the new utility, as we find in this opportunity."

A Phase I multicenter dose-escalation tigecycline trial in patients with relapsed or refractory Acute Myeloid Leukemia ("AML") is currently ongoing at Princess Margret Cancer Centre (UHN), University of California, Los Angeles and the University of Kansas. In addition to addressing safety and tolerability, this trial will also provide important human proof-of-concept data. Biomarkers indicative of on-target effects and inhibition of mitochondrial translation are being assessed at each dose level. Enrolment is proceeding well in this open label, 28-patient trial. Dosing is estimated to be completed in the first half of 2013. SCT projects that a Phase Ib/IIa combination trial can commence in early 2014 provided the necessary funding is secured.

"This opportunity, emerging from Dr. Schimmer's research, targets an unmet medical need in leukemia therapy and is a compelling example of MaRS Innovation's critical role in bridging the technology gap for promising early-stage assets from our members through translational funding and strategic guidance," said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. "We are pleased to have collaborated with UHN and partner with Stem Cell Therapeutics on this exciting project."

SCT has been granted an option by UHN under which, and prior to April 30, 2013,SCT may conclude the exclusive license provided SCT has secured additional financing sufficient to support its product development operations. The worldwide, exclusive license agreement will contain customary provisions regarding an initial license consideration, milestones, royalties on sales and sublicensing terms.

In parallel with its clinical program, SCT plans to devote additional resources to amplify the preclinical R&D program to unlock the potential of tigecycline and its derivatives. The mitochondrial-targeting mechanism-of-action (MOA) could provide an opportunity for synergy with other cancer therapies, thereby expanding tigecycline's use from AML into other types of malignancies.

Dr. Christopher Paige, Vice President, Research at UHN, stated "We are very pleased to have created this partnership with the emerging Canadian biotechnology company, Stem Cell Therapeutics Corp. This is an excellent example of how research hospitals such as the UHN can work with MaRS Innovation and receptor companies to translate cutting-edge Canadian research discoveries into the prospect for important benefits to patients."

About Stem Cell Therapeutics

Visit link:
Stem Cell Therapeutics Announces Agreement With University Health Network and MaRS Innovation for Novel, Clinical ...

NEW YORK, NY--(Marketwire - Nov 8, 2012) - Stem cell stocks have been gaining popularity among investors in 2012 as new and promising research continues to propel the industry forward. A study performed earlier this year at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on Aastrom Biosciences, Inc. ( NASDAQ : ASTM ) and Neostem Inc. ( NYSE : NBS ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/ASTM

http://www.FiveStarEquities.com/NBS

A more recent study, also conducted at Johns Hopkins University, has showed that stem cells donated by strangers were as safe and as effective as the patient's own cells in repairing heart tissue. This is a key advancement for the treatment of heart attack with stem cells, as this possibly means stem cells could be stored for use just as blood is now.

"You could have the cells ready to go in the blood bank so when the patient comes in for a therapy -- there's no delay," said Dr. Joshua Hare of the University of Miami. "It's also cheaper to make the donor cells," as marrow from a single donor could provide enough cells for the treatment of up to 10 people.

Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Aastrom Biosciences is a leader in the development of patient-specific multicellular therapies for the treatment of severe, chronic cardiovascular diseases. Stem cell therapy is the infusion, injection or transplantation of whole cells into a patient for the treatment of a disease or condition.

NeoStem is a provider of adult stem cell collection, processing and storage services in the United States, enabling healthy individuals to donate and store their stem cells for personal therapeutic use. In addition, the company collects and stores cord blood cells of newborns which help to ensure a supply of autologous stem cells for the child should they be needed for future medical treatment.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

Here is the original post:
Promising Stem Cell Research Driving Industry's Growth in 2012